ETON · Eton Pharmaceuticals, Inc.
$63.47
+3.56 (+5.94%)
At close · Aug 21
Market Cap
$1.81B
Shares
28.58M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$79.95M
+104.9%
FY2025
Net Income
-$4.6M
-20.4%
FY2025
Gross Margin
53.46%
-6.6pp
FY2025
Operating Margin
-1.06%
+5.6pp
FY2025
Operating Cash Flow
$10.52M
+986.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| at least $145M | $105.6M | $79.95M | $39.01M | $31.64MG | $21.25M | $21.83M | $39K | $959K | — | |
| — | $44.49M | $37.21M | $15.6M | $10.58M | $6.93M | $2.83M | $436K | $453K | — | |
| — | $61.1M | $42.74M | $23.41M | $21.06M | $14.32M | $19.01M | -$397K | $506K | — | |
| — | — | 53.46% | 60.01% | 66.56% | 67.38% | 87.05% | -1017.95% | 52.76% | — | |
| — | $5.76M | $7.77M | $3.26M | $3.32M | $4M | $6.24M | $14.1M | $11.56M | $5.63M | |
| — | $39.03M | $35.82M | $22.75M | $18.93M | $18.58M | $14.27M | $12.61M | $7.55M | $4.69M | |
| — | — | $4M | $1.1M | $790K | $1.62M | $204K | $150K | $25K | — | |
| — | — | $4.04M | $1.15M | $901K | $66K | $155K | $347K | $283K | $63K | |
| — | $44.79M | $43.58M | $26.01M | $22.25M | $22.58M | $20.5M | $26.71M | $19.11M | $10.32M | |
| — | $16.31M | -$844K | -$2.6M | -$1.19M | -$8.26M | -$1.5M | -$27.11M | -$18.6M | -$10.32M | |
| — | — | -1.06% | -6.66% | -3.77% | -38.87% | -6.85% | -69515.38% | -1939.62% | — | |
| — | — | $3.2M | -$1.45M | -$291K | -$8.19M | -$1.34M | -$26.76M | -$18.32M | -$10.26M | |
| — | — | — | — | $1.06M | $955K | $1.04M | $884K | $98K | — | |
| — | — | -$3.71M | -$1.21M | $503K | -$761K | -$1.01M | -$859K | $281K | $164K | |
| — | $12.75M | -$4.56M | -$3.81M | -$689K | -$9.02M | -$1.96M | -$27.97M | -$18.32M | -$12.74M | |
| — | $63K | $43K | $15K | $247K | $0 | $0 | — | — | — | |
| — | $12.69M | -$4.6M | -$3.82M | -$936K | -$9.02M | -$1.96M | -$27.97M | -$18.32M | -$12.74M | |
| — | — | -5.75% | -9.8% | -2.96% | -42.45% | -8.95% | -71717.95% | -1910.32% | — | |
| — | — | — | — | — | — | — | -$27.97M | -$18.32M | -$37.23M | |
| USD/shares | — | — | -$0.17 | -$0.15 | -$0.04 | -$0.36 | -$0.08 | -$1.33 | — | — |
| shares | — | — | 26.91M | 25.9M | 25.65M | 25.15M | 25.21M | 21.01M | 17.76M | 6.42M |
| shares | — | — | — | — | — | — | 25.21M | 21.01M | 17.76M | 6.42M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
17.19×
Peer median 2.10×
EV/EBIT
111.30×
Peer median 13.89×
P/E (TTM)
—
Peer median 16.47×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product Sales and Royalties | $76,664,000 | $38,511,000 | $26,142,000 | $11,251,000 | $2,832,000 | $39,000 | — |
| License | $3,286,000 | $500,000 | $5,500,000 | $10,000,000 | $19,000,000 | — | — |
| Licensing Revenue | — | — | — | — | — | — | $500,000 |
| Product | — | — | — | — | — | — | $459,000 |
Key facts
CIK
1710340
CUSIP
29772L108
13F (30d)
146 filings
145 filers
Visit website
Investor relations